Full Press Release Details
CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma.
REGN
CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma
Key Takeaway: CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma